There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics Inc (IOVA) and Vertex Pharmaceuticals (VRTX) with bullish sentiments.
Iovance Biotherapeutics Inc (IOVA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics Inc, with a price target of $26. The company’s shares closed yesterday at $11.23.
Pantginis commented:
“Valuation and impediments to achieving price target. We reiterate our Buy rating and price target of $26. Our target is based on our clinical net present value (NPV) model, which derives its primary value from LN-144 for metastatic melanoma currently. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis is a 1-star analyst with an average return of -1.3% and a 35.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Armata Pharmaceuticals Inc.
Iovance Biotherapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.75, implying a 102.6% upside from current levels. In a report issued on May 8, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Vertex Pharmaceuticals (VRTX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Vertex Pharmaceuticals, with a price target of $220. The company’s shares closed yesterday at $166.88.
Fein wrote:
“Valuation and risks to our investment thesis. Our price target of $220/share, is based on an equally weighted composite of: (a) $216/share, as a 30x multiple of taxed and diluted FY26 GAAP EPS of $22.97 discounted back to and (b) an NPV of $224/share (discount rate 11.0%, terminal growth rate of 2.0%).”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 2.8% and a 43.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $208.82, implying a 25.1% upside from current levels. In a report issued on May 1, Oppenheimer also assigned a Buy rating to the stock with a $230 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
